Literature DB >> 26609348

Burden of Gastrointestinal and Liver Diseases in Middle East and North Africa: Results of Global Burden of Diseases Study from 1990 to 2010.

Sadaf Ghajarieh Sepanlou1, Fatemeh Malekzadeh2, Farnaz Delavari3, Mohsen Naghavi4, Mohammad Hossein Forouzanfar4, Maziar Moradi-Lakeh5, Reza Malekzadeh6, Hossein Poustchi6, Akram Pourshams6.   

Abstract

BACKGROUND Gastrointestinal and liver diseases (GILDs) are major causes of death and disability in Middle East and North Africa (MENA). However, they have different patterns in countries with various geographical, cultural, and socio-economic status. We aimed to compare the burden of GILDs in Iran with its neighboring countries using the results of the Global Burden of Disease (GBD) Study in 2010. METHODS Classic metrics of GBD have been used including: age-standardized rates (ASRs) of death, years of life lost due to premature death (YLL), years of life lost due to disability (YLD), and disability adjusted life years (DALY). All countries neighboring Iran have been selected. In addition, all other countries classified in the MENA region were included. Five major groups of gastrointestinal and hepatic diseases were studied including: infections of gastrointestinal tract, gastrointestinal and pancreatobilliary cancers, acute hepatitis, cirrhosis, and other digestive diseases. RESULTS The overall burden of GILDs is highest in Afghanistan, Pakistan, and Egypt. Diarrheal diseases have been replaced by gastrointestinal cancers and cirrhosis in most countries in the region. However, in a number of countries including Afghanistan, Pakistan, Turkmenistan, Egypt, and Yemen, communicable GILDs are still among top causes of mortality and morbidity in addition to non-communicable GILDs and cancers. These countries are experiencing the double burden. In Iran, burden caused by cancers of stomach and esophagus are considerably higher than other countries. Diseases that are mainly diagnosed in outpatient settings have not been captured by GBD. CONCLUSION Improving the infrastructure of health care system including cancer registries and electronic recording of outpatient care is a necessity for better surveillance of GILDs in MENA. In contrast to expensive treatment, prevention of most GILDs is feasible and inexpensive. The health care systems in the region can be strengthened for prevention and control.

Entities:  

Keywords:  Burden; Disability; Gastrointestinal disease; Liver disease; Middle East and North Africa; Mortality

Year:  2015        PMID: 26609348      PMCID: PMC4655840     

Source DB:  PubMed          Journal:  Middle East J Dig Dis        ISSN: 2008-5230


INTRODUCTION

The epidemiological transition can be observed in almost all countries worldwide.[1] As neighboring countries may share geographical, political, and cultural characteristics, the pattern of transition may be somehow similar. However, heterogeneity in health indicators may also be observed due to heterogeneous socio-economic determinants and health system governance and infrastructure. It may be important for policy makers at national level to be aware of the health status in their country compared with their neighbors and other countries with similar socio-economic and cultural determinants. Policy makers can learn lessons from experiences of their neighboring countries in health care promotion. Countries in Middle East and North Africa (MENA) share very important determinants including religion, socio-economic status, and partly ethnicity. However, significant differences in health indicators may also be observed between these countries. Gastrointestinal and liver diseases (GILDs) are among diseases that show variability in the pattern of their prevalence, incidence, mortality and the final burden they impose on societies. While some countries such as Afghanistan and Pakistan are still facing challenges regarding the control of gastrointestinal infectious diseases, other countries with better economy in the region have experienced the obvious transition from communicable to non-communicable GILDs. In the current article, following the previous two articles regarding the burden of GILD in 2010 and its trend since 1990 in Iran, we are presenting the burden and its trend in Iran in comparison with the neighboring countries and other countries in MENA, which have been estimated in Global Burden of Disease (GBD) study 2010.[2,3] We have taken the advantage of the unique metrics developed by GBD that make it possible to compare the health status of countries within the past two decades.

MATERIALS AND METHODS

The methodology of GBD study 2010 has been explained elsewhere in details.[4] The concepts of death, years of life lost due to premature death (YLLs), years of life lost due to disability (YLDs), and the disability adjusted life years (DALYs) are the same as previous reports.[5-9] In the estimates presented here, all countries neighboring Iran have been selected. These countries include: Pakistan, Afghanistan, Turkmenistan, Azerbaijan, Armenia, Turkey, and Iraq. In addition, all other countries classified in the MENA region were included as well. This group of countries consisted of: Algeria, Bahrain, Egypt, Jordan, Kuwait, Lebanon, Libya, Morocco, Palestine, Oman, Qatar, Saudi Arabia, Syria, Tunisia, United Arab Emirates, and Yemen. Five major groups of gastrointestinal and hepatic diseases were studied. These major groups included: infections of gastrointestinal tract, gastrointestinal and hepatobilliary cancers, acute hepatitis, cirrhosis, and other digestive diseases. The age-standardized rates (ASRs) were compared between countries in 2010. Countries were ranked in terms of total deaths and DALYs caused by overall gastrointestinal and hepatic diseases. Furthermore, trend of death and DALYs rates from 1990 to 2010 were also illustrated for all countries.

RESULTS

Figure 1 shows the ASRs of deaths, DALYs, YLLs, and YLDs per 100,000 for all digestive diseases in MENA region in 2010. Afghanistan, Egypt, Pakistan, Turkmenistan, and Yemen are the top five countries in terms of ASRs of deaths, DALYs, YLLs, and YLDs due to all digestive diseases in 2010. Syria, Lebanon, Kuwait, and Saudi Arabia are among the top five countries with the least ASRs of death, DALYs, and YLLs. Iraq is ranked among top five countries with least YLD rates that has replaced Kuwait. Also in 2010, Iran ranked 13th, 15th, 15th, and 12th in terms of ASR for deaths, DALYs, YLLs, and YLDs respectively caused by overall gastrointestinal diseases.
Fig 1
The age standardized rates (ASRs) of death, DALYs, YLLs, and YLDs for all digestive diseases per 100,000 in countries neighboring Iran and other countries in Middle East and North Africa in 2010 Figures 2 to 7 show the ASR for deaths and DALYs in Middle East countries for diarrheal diseases, acute hepatitis, cirrhosis, stomach cancer, esophageal cancer, and colorectal cancer. Rates for diarrheal diseases are highest in Pakistan, Afghanistan, Yemen, Turkmenistan, and Egypt and lowest in Kuwait, Qatar, and Syria. The rates of hepatitis and cirrhosis are highest in Egypt, Pakistan, and Afghanistan and lowest in Syria and Turkey. Rates for stomach cancer are highest in Afghanistan, Iran, and Turkmenistan. The highest rates for esophageal cancer are observed in Turkmenistan, Iran, Pakistan, Afghanistan, and Azerbaijan. Finally, the burden of colorectal cancer is highest in Turkey, Palestine, Armenia, Jordan, and Lebanon.
Fig 2
Fig 7
The age standardized rates of deaths and DALYs per 100,000 caused by diarrheal diseases in Middle East and North Africa DALYs: the disability adjusted life years The age standardized rates of deaths and DALYs per 100,000 caused by all types of acute hepatitis in Middle East and North Africa DALYs: the disability adjusted life years The age standardized rates of deaths and DALYs per 100,000 caused by cirrhosis secondary to all risk factors in Middle East and North Africa DALYs: the disability adjusted life years The age standardized rates of deaths and DALYs per 100,000 caused by stomach cancer in Middle East and North Africa DALYs: the disability adjusted life years The age standardized rates of deaths and DALYs per 100,000 caused by esophageal cancer in Middle East and North Africa DALYs: the disability adjusted life years The age standardized rates of deaths and DALYs per 100,000 caused by colorectal cancer in Middle East and North Africa DALYs: the disability adjusted life years Figures 8 and 9 show the ranking of main gastrointestinal diseases in 24 countries in 2010 by ASRs of death and DALY rates per 100,000 respectively. All data are reported for both sexes. Diarrhea is the first cause for both death rates and DALY rates in the entire region. It is among the top four causes of death in 10 countries and is the first or the second cause of DALY in all countries except for Armenia. Diarrhea ranks 10th and 11th cause of death in Qatar and Kuwait, which is quite different from other countries.
Fig 8
Fig 9
Ranking of main gastrointestinal diseases by death rate in 25 countries in Middle East and neighboring Iran in 2010 MENA: Middle East and North Africa Ranking of main gastrointestinal diseases by DALY rate in 25 countries in Middle East and neighboring Iran in 2010 MENA: Middle East and North Africa Cirrhosis is the second cause of both death and DALY in the region. It is among the top three causes of death and DALY in all countries except for Bahrain. Typhoid and hepatitis are the 3rd and 4th causes of DALYs in the region but they are replaced by stomach cancer and liver cancer as 3rd and 4th causes of death. Stomach cancer is among the top four causes of death in 15 countries and among the top four causes of DALY in 12 countries. The respective figures for liver cancer are 19 and 11 countries. Hepatitis has high rank in Pakistan, Egypt, and Bahrain in terms of both death and DALY rates. Peptic ulcer is the 7th cause of both death and DALY in the region. Colorectal cancer is the 6th cause of death and 8th cause of DALY in the region. Esophageal cancer, pancreatic cancer, gall bladder and billiary cancer, appendicitis, and gastritis and duodenitis are the five diseases causing least deaths and DALYs in the region. The rankings of the first four causes of deaths and DALYs and the last five causes in most countries are almost compatible with the rankings in the entire region. Esophageal cancer has a specifically high rank in Iran and Turkmenistan in terms of both death and DALY. Pancreatic cancer has a specifically high death rate in Lebanon, Palestine, Bahrain, Qatar, and Kuwait. In Iran, diarrhea is the 6th cause of death. The first cause of death is stomach cancer, followed by esophageal cancer, cirrhosis, liver cancer, and colorectal cancer. Stomach cancer is the first cause of DALY in Iran as well followed by diarrhea, cirrhosis, and esophageal cancer. Figures 10 and 11 show the trend of ASRs and number of deaths and DALYs in all ages in 24 countries from 1990 to 2010 for all gastrointestinal and hepatobilliary causes. Figure 12 shows the trend of ASRs and numbers of deaths caused by diarrhea from 1990 to 2010 and figure 13 shows similar estimates for the entire gastrointestinal and pancreatobilliary cancers.
Fig 10
Fig 11
Fig 12
Fig 13
Trend of the rate of deaths and DALYs for all gastrointestinal diseases in 24 countries from 1990 to 2010 Trend of the number of deaths and DALYs for all gastrointestinal diseases in 24 countries from 1990 to 2010 Trends in number and rates of deaths due to diarrhea in 24 countries from 1990 to 2010 Trends in number and rates of deaths due to GI and pancreatobilliary cancers in 24 countries from 1990 to 2010

DISSCUTION

The results of GBD study in MENA show that GILDs impose considerable burden on countries in this region. While the ASRs of deaths and DALYs have decreased in almost all countries in the region, the number of deaths and DALYs due to total GILDs shows rises in some countries such as Qatar, United Arab Emirates, Bahrain, Kuwait, and Palestine. These findings show that the increase in numbers may be due to ageing of the population in spite of decreasing ASRs. The rates and numbers of deaths due to diarrhea have decreased in most countries. For gastrointestinal and hepatobilliary cancers, although the rates of death decreased, the numbers of deaths have increased in all countries. In several countries such as Iran, Turkey, Syria, Kuwait, Lebanon, and Qatar, diarrheal diseases and acute hepatitis have been replaced by gastrointestinal and hepatobilliary malignancies. However, while malignancies impose increasing burden in some countries including Afghanistan, Pakistan, Turkmenistan, Egypt, and Yemen, the burden due to diarrheal diseases and hepatitis is still significant and these countries are suffering from double burden of both communicable and non-communicable GILDs. Existing evidence shows that diarrheal diseases are still quite common in Afghanistan,[10,11] Pakistan,[12,13] Yemen[14] and Egypt.[15] The estimates are specifically made for deaths due to diarrheal diseases among children under 5 years old.[13,16-19], There is compelling evidence on effectiveness of improving hygiene including hand washing and sanitation facilities that significantly reduce the incidence and recurrence of diarrheal diseases.[20-23] Mothers’ education has a substantial role in the home management of diarrhea in children,[24,25] and their health seeking behavior for childhood illnesses.[26] Service packages specifically devised for management of diarrhea are demonstrated to be effective in Pakistan, Egypt, and Yemen.[14,23,27] There is evidence on high prevalence of hepatitis C (>3.5%) and hepatitis B in MENA region.[28,29] However reports about the Maghreb region in Middle East including Algeria, Tunisia, Libya, and Morocco show that the prevalence of hepatitis B and C is low and comparable to developed countries.[30] The prevalence of hepatitis C in Maghreb is also low and comparable to developed countries. In contrast, there is abundant evidence on high prevalence of acute hepatitis of all kinds in Egypt and their subsequent progression to cirrhosis and hepatocellular carcinoma. Hepatitis B and C virus infections are major public health concerns in Egypt.[31,32] The prevalence of hepatitis C virus in Egypt is the highest in the world. About 14.7% of the population in Egypt are antibody positive and hepatitis C has become a massive epidemic in national level.[33,34] Transmission mainly occurs through sexual contact and intravenous drug use.[35] Evidence shows that Afghanistan is also facing a high prevalence of hepatitis B and C infection.[36,37] Intravenous drug use, unsafe sex, unsafe blood transfusion, and vertical transmission are the main routes of transmission.[38-44] Hepatitis B and C infections are prevalent in Pakistan as well and are higher than its neighboring countries such as India and Nepal.[45,46] Unlike hepatitis B, as there is no vaccine available to prevent hepatitis C, the primary prevention should be focused on safe blood transfusion, safe sex, and safe injection of drugs.[28,47] Chronic hepatitis B and C are the main causes of liver cirrhosis and progression to hepatocellular carcinoma. The results of GBD 2010 show that cirrhosis is among the top four causes of death in all countries in MENA except for Bahrain. The death rate caused by cirrhosis in Egypt is by far the highest in the world, followed by Pakistan, Afghanistan, Yemen, and Morocco.[48] Pakistan is specifically experiencing an epidemic of cirrhosis.[49] It is estimated that globally, 30% of cirrhosis is attributable to HBV and another 27% is attributable to HCV.[50] It is also estimated that mortality due to liver cirrhosis imposes substantial burden worldwide each year, causing more than one million deaths in 2010.[48] Its treatment is expensive and unavailable in most parts of the world. Additionally, treatment of cirrhosis does not significantly increase the survival in decompensated forms.[51] However, preventive measures such as safe blood transfusion, hygienic health facilities, vaccination for HBV, screening, and general education are inexpensive and cost-effective.[47,52-55] Preventive measures are highly recommended at national levels especially in low-income countries to tackle this growing public health concern. Hepatocellular carcinoma is another complication of chronic hepatitis. It is estimated that 78% of all cases are attributable to either chronic HBV or HCV infections.[50] In another report, 55% of global hepatocellular carcinoma is attributed to chronic HBV infection.[56] This figure is 89% in endemic regions.[56] Pakistan is specifically experiencing a significant rise in hepatocellular carcinoma secondary to HBV and HCV infections.[57] Although it may seem that the burden of hepatitis B and C infections may be higher in long-term, the burden of acute hepatitis A and E should not be forgotten either.[58-62] Vertical transmission of hepatitis E is not uncommon in Egypt, Afghanistan, and Pakistan.[63] Results of GBD 2010 show that 28% of all deaths and 16% of all DALYs due to GILDs are caused by gastrointestinal and hepatobilliary cancers in MENA. Stomach cancer ranks 3rd as a cause of death and 5th as a cause of DALY in the region. It is among top four causes of death in 15 countries and among top four causes of DALY in 12 countries. The rates of stomach cancer are highest in Afghanistan, Iran, and Turkmenistan. Cancer of stomach is followed by liver cancer, colorectal cancer, esophageal cancer, pancreatic cancer, and gall bladder and hepatobilliary cancer in the entire region. Liver cancer is among the top four causes of death in 18 countries and among the top four causes of DALY in 10 countries. Colorectal cancer has the highest rate of death and DALY in Turkey, Tunisia, Lebanon, and Jordan. The lowest rates are seen in Pakistan. Esophageal cancer is among the top four causes of death and DALY only in Turkmenistan and Iran. The results are compatible with global cancer data (GLOBOCAN) in 2012 in which stomach cancer, liver cancer, colorectal cancer, and esophageal cancer accounted for 8.4%, 8.1%, 7.8%, and 4.6% of all incidental cases respectively in less developed countries.[64] Globally, all gastrointestinal and hepatobilliary cancers accounted for almost 30% of all incidental cases and 37% of all cancer deaths in 2012 based on GLOBOCAN results.[64] Generally speaking, the rates of deaths and DALYs caused by gastrointestinal and hepatobilliary cancers in North African countries are lower than Middle Eastern countries.[64-68] In contrast, specifically in countries located in the Caspian Littoral, esophageal and gastric cancers are higher due to genetic and certain life style exposures.[69-71] Evidence shows that while esophageal cancer in this area is declining,[72] there is a general rise in stomach cancer.[73] A large prospective cohort study, the Golestan Cohort Study (GCS) in Golestan province, north east of Iran, has been conducted on over 50,000 Iranians, mostly of Turkmen ethnicity, to investigate the epidemiology and determinants of upper gastrointestinal malignancies in the Caspian Littoral. This study is the largest cohort study in Middle East.[74,75] The results of this study have shown that low consumption of fruit and vegetable, very hot tea drinking, life style and other aspects of diet, opium and tobacco use, and poor oral health, along with low socio-economic status are the most likely etiologies of high esophageal cancer rate reported in this region.[76-79] Cancer registries are the best existing sources for estimating the prevalence and incidence of major cancers. However, cancer registries in general have two defects: incompleteness and misclassification. Since the first results of national cancer registries were released in 1975, stomach cancer, cancer of the colon and rectum, and esophageal cancer have retained their ranks in the hierarchy of cancers, but there is a steep rise in the prevalence of liver cancer [80-83] in MENA and specifically in Egypt.[84,85] Yet, in effect, the cancers of stomach, colon and rectum, and esophagus are underestimated while the liver cancer is overestimated as metastatic cancers of other sites may be misclassified as liver cancer. Expansion and accuracy of population-based cancer registries is a necessity especially in developing countries for more precise estimations of the burden of cancers.[86] The unique metrics developed and the novel statistical methods used in GBD have made it possible to make estimations for times and places where data is sparse or is of low quality. GBD has used novel methods to overcome these challenges among which, the scarcity and low quality of hospital data and data in outpatient settings are very bold. There is compelling evidence on increasing trend of GILDs that are regularly diagnosed in outpatient setting and have not been captured by GBD. These include but are not restricted to gastroesophageal reflux disease (GERD),[87] inflammatory bowel diseases (IBD),[88,89] irritable bowel syndrome (IBS),[90,91] non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH).[92] DALYs reported in GBD 2010 show regional heterogeneity in the causes of premature death and disability, which highlights the importance of regular epidemiological assessments for every country in the MENA. To further improve precision of the estimated DALYs, qualitative studies should be done in every region to determine how people define quality of life. Collecting high quality evidence is a necessity for policy makers in developing countries in order to effectively allocate the limited resources for prevention and control.

CONFLICT OF INTERESTS

None.

ACKNOWLEDGEMENTS

This study was supported by grants from Iranian Association of Gastroenterology and Hepatology.
  91 in total

1.  Disease profile of children in Kabul: the unmet need for health care.

Authors:  Amarendra Narayan Prasad
Journal:  J Epidemiol Community Health       Date:  2006-01       Impact factor: 3.710

Review 2.  Hepatitis B virus infection, its sequelae, and prevention by vaccination.

Authors:  Li-Min Huang; Chun-Yi Lu; Ding-Shinn Chen
Journal:  Curr Opin Immunol       Date:  2011-01-21       Impact factor: 7.486

3.  Seroprevalence and risk factors for hepatitis B and C virus infection in Damietta Governorate, Egypt.

Authors:  A Edris; M O Nour; O O Zedan; A E Mansour; A A Ghandour; T Omran
Journal:  East Mediterr Health J       Date:  2014-10-20       Impact factor: 1.628

4.  Cost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalence.

Authors:  David D Kim; David W Hutton; Ahmed A Raouf; Mohsen Salama; Ahmed Hablas; Ibrahim A Seifeldin; Amr S Soliman
Journal:  Glob Public Health       Date:  2014-12-03

5.  The impact of household hygiene on the risk of bacterial diarrhea among Egyptian children in rural areas, 2004-2007.

Authors:  Khaled E Hassan; Adel Mansour; Hind Shaheen; Mohamed Amine; Mark S Riddle; Sylvia Y N Young; Peter Sebeny; Samuel Levin
Journal:  J Infect Dev Ctries       Date:  2014-12-15       Impact factor: 0.968

6.  Pattern of preventable diseases in Afghanistan: suggestions to reduce the morbidity and mortality at IGICH.

Authors:  V P Choudhry; I Fazal; G Aram; M Choudhry; L S Arya; M S Torpeki
Journal:  Indian Pediatr       Date:  1989-07       Impact factor: 1.411

7.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

Review 8.  The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis.

Authors:  Yousra A Mohamoud; Ghina R Mumtaz; Suzanne Riome; Dewolfe Miller; Laith J Abu-Raddad
Journal:  BMC Infect Dis       Date:  2013-06-24       Impact factor: 3.090

Review 9.  The epidemiology of hepatitis C virus in the Maghreb region: systematic review and meta-analyses.

Authors:  Fatima A Fadlalla; Yousra A Mohamoud; Ghina R Mumtaz; Laith J Abu-Raddad
Journal:  PLoS One       Date:  2015-03-24       Impact factor: 3.240

10.  Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.

Authors:  Theo Vos; Abraham D Flaxman; Mohsen Naghavi; Rafael Lozano; Catherine Michaud; Majid Ezzati; Kenji Shibuya; Joshua A Salomon; Safa Abdalla; Victor Aboyans; Jerry Abraham; Ilana Ackerman; Rakesh Aggarwal; Stephanie Y Ahn; Mohammed K Ali; Miriam Alvarado; H Ross Anderson; Laurie M Anderson; Kathryn G Andrews; Charles Atkinson; Larry M Baddour; Adil N Bahalim; Suzanne Barker-Collo; Lope H Barrero; David H Bartels; Maria-Gloria Basáñez; Amanda Baxter; Michelle L Bell; Emelia J Benjamin; Derrick Bennett; Eduardo Bernabé; Kavi Bhalla; Bishal Bhandari; Boris Bikbov; Aref Bin Abdulhak; Gretchen Birbeck; James A Black; Hannah Blencowe; Jed D Blore; Fiona Blyth; Ian Bolliger; Audrey Bonaventure; Soufiane Boufous; Rupert Bourne; Michel Boussinesq; Tasanee Braithwaite; Carol Brayne; Lisa Bridgett; Simon Brooker; Peter Brooks; Traolach S Brugha; Claire Bryan-Hancock; Chiara Bucello; Rachelle Buchbinder; Geoffrey Buckle; Christine M Budke; Michael Burch; Peter Burney; Roy Burstein; Bianca Calabria; Benjamin Campbell; Charles E Canter; Hélène Carabin; Jonathan Carapetis; Loreto Carmona; Claudia Cella; Fiona Charlson; Honglei Chen; Andrew Tai-Ann Cheng; David Chou; Sumeet S Chugh; Luc E Coffeng; Steven D Colan; Samantha Colquhoun; K Ellicott Colson; John Condon; Myles D Connor; Leslie T Cooper; Matthew Corriere; Monica Cortinovis; Karen Courville de Vaccaro; William Couser; Benjamin C Cowie; Michael H Criqui; Marita Cross; Kaustubh C Dabhadkar; Manu Dahiya; Nabila Dahodwala; James Damsere-Derry; Goodarz Danaei; Adrian Davis; Diego De Leo; Louisa Degenhardt; Robert Dellavalle; Allyne Delossantos; Julie Denenberg; Sarah Derrett; Don C Des Jarlais; Samath D Dharmaratne; Mukesh Dherani; Cesar Diaz-Torne; Helen Dolk; E Ray Dorsey; Tim Driscoll; Herbert Duber; Beth Ebel; Karen Edmond; Alexis Elbaz; Suad Eltahir Ali; Holly Erskine; Patricia J Erwin; Patricia Espindola; Stalin E Ewoigbokhan; Farshad Farzadfar; Valery Feigin; David T Felson; Alize Ferrari; Cleusa P Ferri; Eric M Fèvre; Mariel M Finucane; Seth Flaxman; Louise Flood; Kyle Foreman; Mohammad H Forouzanfar; Francis Gerry R Fowkes; Richard Franklin; Marlene Fransen; Michael K Freeman; Belinda J Gabbe; Sherine E Gabriel; Emmanuela Gakidou; Hammad A Ganatra; Bianca Garcia; Flavio Gaspari; Richard F Gillum; Gerhard Gmel; Richard Gosselin; Rebecca Grainger; Justina Groeger; Francis Guillemin; David Gunnell; Ramyani Gupta; Juanita Haagsma; Holly Hagan; Yara A Halasa; Wayne Hall; Diana Haring; Josep Maria Haro; James E Harrison; Rasmus Havmoeller; Roderick J Hay; Hideki Higashi; Catherine Hill; Bruno Hoen; Howard Hoffman; Peter J Hotez; Damian Hoy; John J Huang; Sydney E Ibeanusi; Kathryn H Jacobsen; Spencer L James; Deborah Jarvis; Rashmi Jasrasaria; Sudha Jayaraman; Nicole Johns; Jost B Jonas; Ganesan Karthikeyan; Nicholas Kassebaum; Norito Kawakami; Andre Keren; Jon-Paul Khoo; Charles H King; Lisa Marie Knowlton; Olive Kobusingye; Adofo Koranteng; Rita Krishnamurthi; Ratilal Lalloo; Laura L Laslett; Tim Lathlean; Janet L Leasher; Yong Yi Lee; James Leigh; Stephen S Lim; Elizabeth Limb; John Kent Lin; Michael Lipnick; Steven E Lipshultz; Wei Liu; Maria Loane; Summer Lockett Ohno; Ronan Lyons; Jixiang Ma; Jacqueline Mabweijano; Michael F MacIntyre; Reza Malekzadeh; Leslie Mallinger; Sivabalan Manivannan; Wagner Marcenes; Lyn March; David J Margolis; Guy B Marks; Robin Marks; Akira Matsumori; Richard Matzopoulos; Bongani M Mayosi; John H McAnulty; Mary M McDermott; Neil McGill; John McGrath; Maria Elena Medina-Mora; Michele Meltzer; George A Mensah; Tony R Merriman; Ana-Claire Meyer; Valeria Miglioli; Matthew Miller; Ted R Miller; Philip B Mitchell; Ana Olga Mocumbi; Terrie E Moffitt; Ali A Mokdad; Lorenzo Monasta; Marcella Montico; Maziar Moradi-Lakeh; Andrew Moran; Lidia Morawska; Rintaro Mori; Michele E Murdoch; Michael K Mwaniki; Kovin Naidoo; M Nathan Nair; Luigi Naldi; K M Venkat Narayan; Paul K Nelson; Robert G Nelson; Michael C Nevitt; Charles R Newton; Sandra Nolte; Paul Norman; Rosana Norman; Martin O'Donnell; Simon O'Hanlon; Casey Olives; Saad B Omer; Katrina Ortblad; Richard Osborne; Doruk Ozgediz; Andrew Page; Bishnu Pahari; Jeyaraj Durai Pandian; Andrea Panozo Rivero; Scott B Patten; Neil Pearce; Rogelio Perez Padilla; Fernando Perez-Ruiz; Norberto Perico; Konrad Pesudovs; David Phillips; Michael R Phillips; Kelsey Pierce; Sébastien Pion; Guilherme V Polanczyk; Suzanne Polinder; C Arden Pope; Svetlana Popova; Esteban Porrini; Farshad Pourmalek; Martin Prince; Rachel L Pullan; Kapa D Ramaiah; Dharani Ranganathan; Homie Razavi; Mathilda Regan; Jürgen T Rehm; David B Rein; Guiseppe Remuzzi; Kathryn Richardson; Frederick P Rivara; Thomas Roberts; Carolyn Robinson; Felipe Rodriguez De Leòn; Luca Ronfani; Robin Room; Lisa C Rosenfeld; Lesley Rushton; Ralph L Sacco; Sukanta Saha; Uchechukwu Sampson; Lidia Sanchez-Riera; Ella Sanman; David C Schwebel; James Graham Scott; Maria Segui-Gomez; Saeid Shahraz; Donald S Shepard; Hwashin Shin; Rupak Shivakoti; David Singh; Gitanjali M Singh; Jasvinder A Singh; Jessica Singleton; David A Sleet; Karen Sliwa; Emma Smith; Jennifer L Smith; Nicolas J C Stapelberg; Andrew Steer; Timothy Steiner; Wilma A Stolk; Lars Jacob Stovner; Christopher Sudfeld; Sana Syed; Giorgio Tamburlini; Mohammad Tavakkoli; Hugh R Taylor; Jennifer A Taylor; William J Taylor; Bernadette Thomas; W Murray Thomson; George D Thurston; Imad M Tleyjeh; Marcello Tonelli; Jeffrey A Towbin; Thomas Truelsen; Miltiadis K Tsilimbaris; Clotilde Ubeda; Eduardo A Undurraga; Marieke J van der Werf; Jim van Os; Monica S Vavilala; N Venketasubramanian; Mengru Wang; Wenzhi Wang; Kerrianne Watt; David J Weatherall; Martin A Weinstock; Robert Weintraub; Marc G Weisskopf; Myrna M Weissman; Richard A White; Harvey Whiteford; Steven T Wiersma; James D Wilkinson; Hywel C Williams; Sean R M Williams; Emma Witt; Frederick Wolfe; Anthony D Woolf; Sarah Wulf; Pon-Hsiu Yeh; Anita K M Zaidi; Zhi-Jie Zheng; David Zonies; Alan D Lopez; Christopher J L Murray; Mohammad A AlMazroa; Ziad A Memish
Journal:  Lancet       Date:  2012-12-15       Impact factor: 79.321

View more
  11 in total

1.  Epidemiology of Gastric Cancer in North Africa and the Middle East from 1990 to 2017.

Authors:  Yousef Ramazani; Ehsan Mardani; Farid Najafi; Mahdi Moradinazar; Mahin Amini
Journal:  J Gastrointest Cancer       Date:  2020-10-14

2.  Liver Cirrhosis, Etiology and Clinical Characteristics Disparities Among Minority Population.

Authors:  Muhammad Abu Tailakh; Liat Poupko; Najwan Kayyal; Ali Alsana; Asia Estis-Deaton; Ohad Etzion; Alexander Fich; David Yardni; Naim Abu-Freha
Journal:  J Immigr Minor Health       Date:  2021-08-28

Review 3.  Saudi Experts Consensus on Diagnosis and Management of Pediatric Functional Constipation.

Authors:  Dhafer B Alshehri; Haifa Hasan Sindi; Ibrahim Mohamod AlMusalami; Ibrahim Hosamuddin Rozi; Mohamed Shagrani; Naglaa M Kamal; Najat Saeid Alahmadi; Samia Saud Alfuraikh; Yvan Vandenplas
Journal:  Pediatr Gastroenterol Hepatol Nutr       Date:  2022-05-09

4.  Burden of gastrointestinal and liver diseases in India, 1990-2016.

Authors:  Dyuti Shah; Govind K Makharia; Uday C Ghoshal; Sanskriti Varma; Vineet Ahuja; Susan Hutfless
Journal:  Indian J Gastroenterol       Date:  2018-10-10

Review 5.  Pharmacotherapies for fatigue in chronic liver disease (CLD): a systematic review and meta-analysis (protocol).

Authors:  Andem Effiong; Prerna Kumari
Journal:  Syst Rev       Date:  2018-02-14

6.  Incidence of Intestinal Infectious Diseases due to Protozoa and Bacteria in Mexico: Analysis of National Surveillance Records from 2003 to 2012.

Authors:  Daniel Diaz; Aldo M Vazquez-Polanco; Jesus Argueta-Donohue; Christopher R Stephens; Francisco Jimenez-Trejo; Santa E Ceballos-Liceaga; Natalia Mantilla-Beniers
Journal:  Biomed Res Int       Date:  2018-07-15       Impact factor: 3.411

Review 7.  Childhood Diarrhoea in the Eastern Mediterranean Region with Special Emphasis on Non-Typhoidal Salmonella at the Human⁻Food Interface.

Authors:  Ali Harb; Mark O'Dea; Sam Abraham; Ihab Habib
Journal:  Pathogens       Date:  2019-05-06

8.  Epidemiology of gastric cancer in Africa: a systematic review and meta-analysis protocol.

Authors:  Celestin Danwang; Jean Joel Bigna
Journal:  Syst Rev       Date:  2019-11-13

9.  Point-of-Care Ultrasound Training: An Assessment of Interns' Needs and Barriers to Training.

Authors:  Waleed Jarwan; Abdullah A Alshamrani; Afnan Alghamdi; Naveed Mahmood; Yousuf M Kharal; Rajkumar Rajendram; Arif Hussain
Journal:  Cureus       Date:  2020-10-28

Review 10.  Circulating non-coding RNAs as potential diagnostic biomarkers in liver diseases.

Authors:  Fedra Mokhtari; Seyed Reza Mohebbi; Afsaneh Sharifian; Marzieh Ramandi; Mohammad Reza Razzaghi
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2021
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.